Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics Q4 2023 Earnings Report

Scinai Immunotherapeutics logo
$2.01 +0.09 (+4.69%)
Closing price 04/17/2025 03:42 PM Eastern
Extended Trading
$2.04 +0.03 (+1.49%)
As of 04/17/2025 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scinai Immunotherapeutics EPS Results

Actual EPS
-$240.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scinai Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scinai Immunotherapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Scinai Immunotherapeutics' Q4 2024 earnings is scheduled for Wednesday, May 21, 2025

Earnings Documents

Scinai Immunotherapeutics Earnings Headlines

Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Scinai Immunotherapeutics Ltd. (SCNI)
See More Scinai Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics (NASDAQ:SCNI), a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

View Scinai Immunotherapeutics Profile

More Earnings Resources from MarketBeat